Bilagra Syrup 60 ml

Babies: It is applicable for babies. Lactating mother: It is not applicable for lactating mothers.
Pregnancy: It is not applicable for pregnancy. Driving: It is not applicable for driving.
Alcohol: It is not applicable for alcohol. Liver: Safe if it is prescribed.
Kidney: Safe if it is prescribed..

Vomiting Nausea Stomach pain Constipation Dizziness Sleepiness Fatigue Headache.

Bilagra syrup is an antihistamine. It works by blocking the histamine produced in the body during an allergic state.
It also lowers your child’s immune system response to these conditions, thereby reducing the symptoms..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• Try to give these medicines at the same time each day to help you remember • Your child may feel sleepy or dizzy after each dose of bilagra syrup. If this happens, make your child sit or lie down and ask them to be careful while performing tasks that require mental focus • Avoid giving bilagra syrup with fatty meals and fruit juice as both can reduce the absorption of the medicine • Bilagra syrup can trigger constipation in your child.
Give plenty of fluids and a fibre-rich diet to your child • Do not share your child's medicines with other medicines.

• Bilagra + Acrivastine: Concurrent use of leads to increase the risk or severity of qtc prolongation • Bilagra + Adenosine: Concurrent use leads to an increase in the risk or severity of qtc prolongation • Bilagra + Ajmaline: Concurrent use of leads to increase the risk or severity of qtc prolongation • Bilagra + Alfuzosin: Concurrent leads to increase the risk or severity of qtc prolongation • Bilagra + Amantadine: Concurrent use leads to an increase in the risk or severity of qtc prolongation • Bilagra + Chlorprothixene: Concurrent use leads to an increase in the risk or severity of qtc prolongation • Bilagra + Clomipramine: Concurrent use leads to an increase in the risk or severity of qtc prolongation.